Company intelligence / Profile preview
Aston Sci
Seoul, South Koreaastonsci.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Aston Sci is a clinical-stage biopharmaceutical company developing innovative immunotherapies, particularly therapeutic cancer vaccines. The company has received US FDA approval to initiate a Phase 2 trial for its ovarian cancer vaccine AST‑201, as well as regulatory approval in Taiwan to begin a Phase 2 trial of AST‑301 targeting HER2-expressed gastric cancers. Other pipeline assets are in earlier stages targeting various oncology indications[5].
- Therapeutic areas
- Oncology
- Modalities
- Therapeutic vaccinesmRNA vaccinesDNA vaccinesSmall molecule drugsBiological products[3][5]
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
EpiThany Inc. (USA) – strategic partnership established in the company's early years[1].No other major partnerships disclosed.
Beyond the preview
Go deeper on Aston Sci.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aston Sci.